

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT**

This announcement does not constitute an offer to sell, or an invitation to offer or buy or subscribe for, securities. An investment in the Offered Shares involves substantial risks and uncertainties. Prospective investors must read the entire Prospectus, and, in particular, should read Section 2 (Risk Factors) for a discussion of certain factors that should be considered in connection with an investment in the Offered Shares, including the risks relating to the fact that (i) Hyloris has a limited operating history and has not yet generated any substantial revenues. Hyloris has incurred operating losses, negative operating cash flows and an accumulated deficit since inception resulting in a negative equity at the date of the Prospectus and Hyloris may not be able to achieve or subsequently maintain profitability. Hyloris is executing its strategy in accordance with its business model, the viability of which has not been demonstrated, (ii) Hyloris' performance depends primarily on the success of its product candidates, a majority of which are in the early reformulation development stage and have not yet received FDA approval of the 505(b)(2) application or ANDA or the other approvals required before they may be commercially launched, (iii) even if Hyloris receives regulatory approval for any of its product candidates, it may be unable to launch the product successfully and the revenue that Hyloris generates from sales of such product, if any, may be limited, (iv) Hyloris has entered into arrangements with related parties and these arrangements present potential conflicts of interest, (v) certain of Hyloris' directors and members of Hyloris' executive management hold directorships or shareholdings in other pharmaceutical companies, which could create potential conflicts of interest, and (vi) after closing of the Offering, certain significant shareholders of the Issuer may have different interests from the Issuer and/or from the minority shareholders and may be able to control the Issuer, including the outcome of shareholder votes. Every decision to invest in the Offered Shares must be based on all information provided in the Prospectus. Potential investors must be able to bear the economic risk of an investment in the Offered Shares and to undergo a full or partial loss of their investment.



**Press Release  
Regulated Information**

**Hyloris Pharmaceuticals announces the end of the stabilisation period and the partial exercise of the Over-allotment Option in connection with its initial public offering**

**Liège (Belgium), 31 July 2020, 08h40 (CEST) – regulated information** – Today, Hyloris Pharmaceuticals SA NV ("**Hyloris**" or the "**Company**"), announces the end of the stabilisation period in the framework of its initial public offering of new shares with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol "HYL" (the "**Offering**").

Within the framework of the Offering, KBC Securities NV/SA ("**KBC Securities**"), acting on behalf of the Underwriters (as defined below), was appointed by the Company as stabilisation manager (the "**Stabilisation Manager**"), and was granted (and subscribed for) an over-allotment option (in the form of a warrant) to subscribe for 862,500 additional new shares at the final offering price of EUR 10.75 per share in order to cover any over-allotments or short positions in relation to the Offering (the "**Over-allotment Option**"). The Over-allotment Option was exercisable for a period of 30 calendar days following the first day on which the shares were admitted to trading on the regulated market of Euronext Brussels (*i.e.*, 29 June 2020).

The Over-allotment Option was partially exercised by the Stabilisation Manager, on behalf of the Underwriters, and 240,000 additional new shares have been issued on 31 July 2020, so that the Company raised an additional EUR 2.58 million in gross proceeds in the context of the Offering.

As a result, the total number of new shares issued by the Company in the context of the Offering amounts to 5,990,000 new shares, and the total gross proceeds raised in the context of the Offering amounts to EUR 64.39 million.

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT**

Following the partial exercise of the Over-allotment Option, the Company has currently 25,832,632 outstanding shares.

The stabilisation period commenced on 29 June 2020 and ended on 29 July 2020.

For an overview of the dilution resulting from the Offering, reference is made to Section 11 "Significant Shareholders" of the Prospectus prepared by the Company in connection with the Offering and available on the Company's website ([www.hyloris.com](http://www.hyloris.com)).

In accordance with Article 6(3) of the Commission Delegated Regulation (EU) 2016/1052 and Article 5, §2 of the Royal Decree of 17 May 2007, KBC Securities, as Stabilisation Manager, undertook stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU 596/2014)) of the following securities within the framework of the Offering:

Issuer:	Hyloris Pharmaceuticals SA
Securities:	Common Shares (BE0974363955)
Size of the Offering:	6,612,500 common shares without nominal value
Offer price:	EUR 10.75 per share
Regulated market:	Euronext Brussels
Ticker:	HYL
Stabilisation Manager:	KBC Securities NV/SA

**Stabilisation transactions<sup>(1)</sup>:**

Trading day	Lowest paid price (EUR)	Highest paid price (EUR)	Stabilisation Trading Venue
29/09/2020	10.2500	10.7500	Euronext Brussels
30/06/2020	10.4200	10.6600	Euronext Brussels
01/07/2020	10.5000	10.7200	Euronext Brussels
02/07/2020	10.5000	10.7400	Euronext Brussels
03/07/2020	10.5000	10.6000	Euronext Brussels
06/07/2020	10.5000	10.6000	Euronext Brussels
07/07/2020	10.5200	10.6400	Euronext Brussels
08/07/2020	10.5000	10.6000	Euronext Brussels
09/07/2020	10.5600	10.6600	Euronext Brussels
10/07/2020	10.6000	10.7000	Euronext Brussels
13/07/2020	10.6400	10.7400	Euronext Brussels
14/07/2020	10.7000	10.7400	Euronext Brussels
15/07/2020	10.6800	10.7400	Euronext Brussels
16/07/2020	10.7000	10.7400	Euronext Brussels
17/07/2020	10.7200	10.7400	Euronext Brussels
20/07/2020	10.6600	10.7400	Euronext Brussels
21/07/2020	10.6800	10.7400	Euronext Brussels
22/07/2020	10.7000	10.7400	Euronext Brussels

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT**

Trading day	Lowest paid price (EUR)	Highest paid price (EUR)	Stabilisation Trading Venue
23/07/2020	10.7000	10.7400	Euronext Brussels
24/07/2020	10.7000	10.7400	Euronext Brussels
27/07/2020	10.7000	10.7400	Euronext Brussels
28/07/2020	10.7000	10.7400	Euronext Brussels
29/07/2020	10.7000	10.7400	Euronext Brussels

#### Note

(1) All data contained in the table above have been provided by the Stabilisation Manager.

During the stabilisation period (29 June 2020 through 29 July 2020), the stabilisation was carried out with respect to a total of 622,500 shares. For more information on the stabilisation transactions that were carried out in the period of 29 June 2020 until 16 July 2020, reference is made to the announcements that were published during the stabilisation period on 7 and 16 July 2020. For more information on the stabilisation transactions that were carried out in the period of 17 July 2020 until 29 July 2020, reference is made to the annex to this announcement.

#### Underwriters involved in the Offering

KBC Securities NV/SA and Van Lanschot Kempen Wealth Management N.V. acted as Joint Global Coordinators and Joint Bookrunners in the Offering (together, the "**Underwriters**").

-Ends-

#### For more information, please contact:

##### Hyloris Pharmaceuticals

Stijn Van Rompay, CEO

+32 (0)4 346 02 07

[contact@hyloris.com](mailto:contact@hyloris.com)

##### Consilium Strategic Communications

Amber Fennell, Chris Welsh, Lucy Featherstone, Taiana De Ruyck Soares

+44 20 3709 5700

[hyloris@consilium-comms.com](mailto:hyloris@consilium-comms.com)

#### Note to Editors

##### About Hyloris Pharmaceuticals SA

Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris' portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid

***NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT***

analgesic product for the treatment of pain, developed with the Company's partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company's wider portfolio. Read more at [www.hyloris.com](http://www.hyloris.com). Hyloris stands for "high yield, lower risk" and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.

### **Important Information**

The material set forth herein is for informational purposes only and does not constitute an offer of securities for sale or a solicitation of any offer to buy securities in the United States, Australia, Canada, Switzerland, Israel, Japan or South Africa or any other jurisdiction in which such an offer or solicitation is unlawful. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state in the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws. No public offering of securities has been or will be made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Switzerland, Israel, Japan or South Africa, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Switzerland, Japan or South Africa. Copies of this material are not being, and should not be, distributed or sent, directly or indirectly, into the United States, Australia, Canada, Switzerland, Israel, Japan or South Africa.

This information does not contain a solicitation for money, securities or other consideration and, if sent in response to the information contained herein, will not be accepted. This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the Company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Any purchase of, subscription for or application for, Shares in the Company to be issued in connection with the Offering should only be made on the basis of information contained in the Prospectus issued by the Company, and published on the Company's website ([www.hyloris.com](http://www.hyloris.com)) in connection with the Offering and any supplements thereto, as the case may be. Potential investors must read the entire Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the securities. This document is not a Prospectus. The Prospectus contains detailed information about the Company and its management, risks associated with investing in the Company, as well as financial statements and other financial data.

Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing the entire amount invested. Persons considering such investments should consult an authorized person specializing in advising on such investments. This announcement does not constitute a recommendation concerning the Offering. An investment in Shares entails significant risks, as the value of the Shares can decrease as well as increase.

***NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT***

This announcement is addressed to and directed at persons in member states of the European Economic Area ("EEA") other than Belgium pursuant to applicable exemptions under the Prospectus Regulation, including but not limited to "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation. In addition, in the United Kingdom, this announcement is only addressed to and directed at (i) persons having professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities, etc. falling within Article 49(2)(a) to (d) of the Order, and (iii) any other person to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). The Offering, as the case may be, is only available to, and any invitation, offer or agreement to subscribe for, purchase, or otherwise acquire securities is engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

KBC Securities NV/SA and Van Lanschot Kempen Wealth Management N.V. (the "Joint Global Coordinators") are acting for the Company and no one else in relation to the Offering, and will not be responsible to anyone other than the Company for providing the protections offered to their respective clients nor for providing advice in relation to the Offering.

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT**

## Annex

Transactions concerning the stabilisation from 17 July 2020 until 29 July 2020<sup>(1)</sup>

Date	Quantity	Price (EUR)	Number of transactions	Stabilisation Trading Venue
17/07/2020	1,778	10.7200	8	Euronext Brussels
17/07/2020	1,545	10.7400	24	Euronext Brussels
DAY TOTAL 17/07/2020	3,323	10.7293	32	Euronext Brussels
20/07/2020	243	10.6600	1	Euronext Brussels
20/07/2020	1,000	10.7000	5	Euronext Brussels
20/07/2020	2,800	10.7200	10	Euronext Brussels
20/07/2020	1,907	10.7400	19	Euronext Brussels
DAY TOTAL 20/07/2020	5,950	10.7206	35	Euronext Brussels
21/07/2020	805	10.6800	1	Euronext Brussels
21/07/2020	1,303	10.7000	7	Euronext Brussels
21/07/2020	495	10.7200	3	Euronext Brussels
21/07/2020	976	10.7400	10	Euronext Brussels
DAY TOTAL 21/07/2020	3,579	10.7092	21	Euronext Brussels
22/07/2020	3,354	10.7000	17	Euronext Brussels
22/07/2020	1,878	10.7200	7	Euronext Brussels
22/07/2020	2,384	10.7400	10	Euronext Brussels
DAY TOTAL 22/07/2020	7,616	10.7174	34	Euronext Brussels
23/07/2020	1,738	10.7000	6	Euronext Brussels
23/07/2020	1,635	10.7400	20	Euronext Brussels
DAY TOTAL 23/07/2020	3,373	10.7194	26	Euronext Brussels
24/07/2020	5,435	10.7000	27	Euronext Brussels
24/07/2020	485	10.7200	4	Euronext Brussels
24/07/2020	821	10.7400	4	Euronext Brussels
DAY TOTAL 24/07/2020	6,741	10.7063	35	Euronext Brussels
27/07/2020	1,907	10.7000	14	Euronext Brussels
27/07/2020	155	10.7200	2	Euronext Brussels
27/07/2020	1,995	10.7400	14	Euronext Brussels
DAY TOTAL 27/07/2020	4,057	10.7204	30	Euronext Brussels
28/07/2020	1,428	10.7000	14	Euronext Brussels
28/07/2020	385	10.7200	7	Euronext Brussels
28/07/2020	187	10.7400	2	Euronext Brussels
DAY TOTAL 28/07/2020	2,000	10.7076	23	Euronext Brussels
29/07/2020	3,575	10.7000	17	Euronext Brussels

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS ANNOUNCEMENT**

<b>Date</b>	<b>Quantity</b>	<b>Price (EUR)</b>	<b>Number of transactions</b>	<b>Stabilisation Trading Venue</b>
29/07/2020	1,322	10.7200	7	Euronext Brussels
29/07/2020	1,171	10.7400	11	Euronext Brussels
DAY TOTAL 29/07/2020	6,068	10.7121	35	Euronext Brussels

**Note**

- (1) All data contained in the table above have been provided by the Stabilisation Manager.